FindTrial
Sign In

Utility Of Cancer Ratio And Cancer Plus Ratio In Differentiating Malignant Pleural Effusion And Tubercular Pleural Effusion.

Utility Of Cancer Ratio(serum LDH/pleural fluid ADA) And Cancer Plus Ratio(cancer ratio/pleural fluid lymphocyte percentage) In Differentiating Malignant Pleural Effusion And Tubercular Pleural Effusion. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065096
Enrollment
179
Registered
2024-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J90- Pleural effusion, not elsewhere classified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Kasturba Medical College Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients Hospitalized In Kasturba Medical Hospital Consecutively For Lymphocytic Predominant Exudative Pleural Effusion

Exclusion criteria

Exclusion criteria: Patients With Transudative Pleural Effusion Patients With Neutrophilic Predominant Exudative Pleural Effusion Clinical Conditions That Increase Serum LDH(Sepsis,Cva,Hemolytic anemia,Hemolyzed samples,Hepatitis)

Design outcomes

Primary

MeasureTime frame
Calculating Cancer Ratio And Cancer Plus RatioTimepoint: Baseline—

Secondary

MeasureTime frame
Efficacy Of Cancer And Cancer Plus Ratio In Differentiating Malignant And Tubercular Pleural Effusion.Timepoint: At Time Of Discharge—

Countries

India

Contacts

Public ContactDr Raghavendra Rao S

Kasturba Medical College Manipal

rags.rao@manipal.edu9901730924

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026